These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 15177501

  • 1. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2.
    Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M.
    Eur J Cancer; 2004 Jun; 40(9):1412-7. PubMed ID: 15177501
    [Abstract] [Full Text] [Related]

  • 2. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma.
    Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M.
    J Exp Ther Oncol; 2003 Jun; 3(4):161-8. PubMed ID: 14567287
    [Abstract] [Full Text] [Related]

  • 3. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
    Safwat A, Schmidt H, Bastholt L, Fode K, Larsen S, Aggerholm N, von der Maase H.
    Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
    [Abstract] [Full Text] [Related]

  • 4. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 5. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X, Zhang W, Wan T, Yu Y, Tao Q, Wang J.
    J Exp Clin Cancer Res; 1999 Jun 01; 18(2):173-9. PubMed ID: 10464704
    [Abstract] [Full Text] [Related]

  • 6. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL, Stampfl S, Zimmerman RJ.
    Cancer Res; 1987 Aug 01; 47(15):3948-53. PubMed ID: 3496953
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
    Lumsden AJ, Codde JP, Van der Meide PH, Gray BN.
    Anticancer Res; 1996 Aug 01; 16(3A):1145-54. PubMed ID: 8702226
    [Abstract] [Full Text] [Related]

  • 10. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases.
    Dezso B, Haas GP, Hamzavi F, Kim S, Montecillo EJ, Benson PD, Pontes JE, Maughan RL, Hillman GG.
    Clin Cancer Res; 1996 Sep 01; 2(9):1543-52. PubMed ID: 9816331
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
    Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA.
    J Immunol; 1984 Apr 01; 132(4):2123-8. PubMed ID: 6607956
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
    Puri RK, Travis WD, Rosenberg SA.
    Cancer Res; 1989 Feb 15; 49(4):969-76. PubMed ID: 2783561
    [Abstract] [Full Text] [Related]

  • 19. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG.
    Clin Cancer Res; 1997 Sep 15; 3(9):1661-7. PubMed ID: 9815857
    [Abstract] [Full Text] [Related]

  • 20. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
    Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ.
    Clin Cancer Res; 2009 Apr 01; 15(7):2323-34. PubMed ID: 19318483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.